Navidea Biopharmaceuticals Inc (NAVB)

[umiak]

Why NAVB is undervalued:

Navidea is seeking marketing approval for Lymphoseek in the EU for use in ILM, a surgical oncology procedure in which lymph nodes draining the area around a tumor are identified and biopsied to determine if cancer has spread to the lymph nodes. The Lymphoseek MAA has proposed the use of the agent in general lymphatic mapping not restricted to any particular solid tumor type

The company will seek the FDA’s nod for marketing Lymphoseek in other types of cancer such as prostate and lung – opening up a potential global market of 8.6 million solid tumors a year, compared with 310,000 U.S. cases yearly of just breast cancer and melanoma.

Half of that to be conservative--4.3M tumors*$300= $1.3B. NAVB could easily have a market cap of $3B.

Not even counting diagnostic potential for Alzheimer's.(P3 is underway) At any rate when LS expands useage approval and becomes standard of care CAH will charge more than $300. That may even prompt the buyout.

Current MC $333M with a $5 pps $595M. Personally I argue $5 is still undervalued with broad EU approval 2H 2013. We have seen this before, with expanded potential come the upgrades.

Year end 2013 target $5:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88483182

Yesterday's web cast, flip through for pipeline, market, competitive advantages, EU partner update 13:52, reports from hospitals now using LS:

http://wsw.com/webcast/jmp21/NAVB/

What got my attention:
During Q&A he mentions a collaborator that reports increasing the number of patients he can serve in a day by 3.(surgery patients)

Once administered LS takes 15 minutes, not 2 hrs to do it's thing, +++ the actual surgery time is reduced because of reduced false positives. (this is my add, not mentioned in the Q&A. but mentioned elsewhere in NAVB DD)